AF
RNAC icon

Amalgamated Financial’s Cartesian Therapeutics RNAC Stock Holding History

Amalgamated Financial’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$14K Buy
+385
New +$24.1K ﹤0.01% 2836

Other funds holding RNAC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
N
NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Amalgamated Financial's RNAC Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Cartesian Therapeutics (RNAC) in Q1 2022: 385 shares worth $14K. The stake represents ﹤0.01% of the portfolio and ranks #2836 among its holdings.

102 funds tracked by Wall St. Rank hold RNAC as of Q1 2022.

  • Amalgamated Financial held 385 shares of Cartesian Therapeutics worth $14K as of Q1 2022.
  • Cartesian Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Cartesian Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2836 holding.
  • 102 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.